Skip to main content

EIT Health ventures and projects in cancer therapy and detection

cancer therapy EIT Change ventures

EIT Health promotes entrepreneurship and innovates in healthy living and active ageing, with the goal of improving the quality of life of Europe’s citizens and the sustainability of healthcare systems.

Two EIT Health-supported ventures are making waves in the field of cancer therapy.

Peptomyc S.L. is a spin-off company of the Vall d’Hebron Institute of Oncology (VHIO) and ICREA in Barcelona, Spain, created to develop a new, first-in-class cancer therapy using innovative anti-Myc peptides based on Omomyc, the best Myc inhibitor known to date.

Myc is an oncogene deregulated in the majority of human cancers. However, a Myc inhibitor has yet to become clinically available. Omomyc has proven to be effective against several types of tumors independently of their mutational status, without evidence of any resistance to it even after long-term treatment, and causing only very mild and reversible side effects in normal tissues.

Different to most common therapies, which are being applicable to specific subsets of the patient population, Peptomyc’s products have the potential to treat all cancer patients, regardless of their mutational status. Its goal is to develop its products through pre-clinical phase and phase I/II clinical trials, to then license to a Big Pharma. With the additional EUR 4.2 million received in financing in mid-September, the spin-off will have the capital necessary to significantly advance the peptides’ industrial CMC manufacturing and validation.

Tubulis Technologies is a pre-start-up project affiliated with the Ludwig Maximilians University (LMU) Munich and the Leibniz-Institut für Molekulare Pharmakologie (FMP) Berlin.

Its goal is to provide the next generation of highly defined, effective and stable Antibody Drug Conjugates (ADCs), which are designed to deliver chemotherapeutic drugs specifically at the tumour site, preventing side-effects in healthy tissues and cells.

The company will focus on the development of cutting-edge technologies, such as the chemo-enzymatic conjugation technique Tub-tag®, for site-specific antibody conjugation, thereby providing the ‘molecular glue’ for efficient drug attachment. For this purpose, Tubulis integrates biotechnological and chemical expertise with proprietary know-how to promote ADC homogeneity and overall stability, ultimately widening the therapeutic window for ADCs.

Other EIT-Health supported innovation projects that focus on cancer treatment and detection include:

LUCINDA - Early Lung Cancer Diagnosis Using Artificial Intelligence and Big Data

Rare Cancer KIC – a new Innovation Community to generate valued benefits for patients and market sustainability.

I4PCM – a common data platform addressing current challenges in cancer medicine

STHLM3 Risk Score – a clinical test to introduce, assess and refine a new application for individualised prostate cancer risk

Catch up with the latest news from the EIT Community in the Newsroom.

Subscribe to the EIT Newsletter to get the best of the EIT Community's news in your inbox once each month.

Do you use social media? Follow us and get updates in your news feed.